Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $10.26 and last traded at $11.00, with a volume of 1857645 shares trading hands. The stock had previously closed at $13.05.

A number of research analysts recently issued reports on CNCE shares. ValuEngine downgraded Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. TheStreet downgraded Concert Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Friday, March 1st. HC Wainwright restated a “buy” rating on shares of Concert Pharmaceuticals in a research note on Friday, March 1st. Zacks Investment Research downgraded Concert Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 5th. Finally, BidaskClub downgraded Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $21.00.

The firm has a market cap of $258.83 million, a price-to-earnings ratio of -4.48 and a beta of 1.00.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.15). Concert Pharmaceuticals had a negative net margin of 533.31% and a negative return on equity of 29.33%. On average, equities analysts forecast that Concert Pharmaceuticals Inc will post -3.32 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in CNCE. Perceptive Advisors LLC bought a new position in Concert Pharmaceuticals in the 4th quarter valued at $22,823,000. RTW Investments LP bought a new position in Concert Pharmaceuticals in the 4th quarter valued at $9,900,000. First Manhattan Co. grew its position in Concert Pharmaceuticals by 85.8% in the 4th quarter. First Manhattan Co. now owns 1,049,534 shares of the biotechnology company’s stock valued at $13,171,000 after acquiring an additional 484,739 shares during the last quarter. Millennium Management LLC grew its position in Concert Pharmaceuticals by 87.2% in the 4th quarter. Millennium Management LLC now owns 1,011,753 shares of the biotechnology company’s stock valued at $12,698,000 after acquiring an additional 471,312 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Concert Pharmaceuticals by 13.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,069,495 shares of the biotechnology company’s stock valued at $15,872,000 after acquiring an additional 126,053 shares during the last quarter. Institutional investors own 75.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2019/04/10/concert-pharmaceuticals-cnce-sets-new-52-week-low-at-10-26.html.

About Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

See Also: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.